Skip to content
Catalyst

Emblica officinalisFinding

Emblica officinalis decreases C-reactive protein concentration

lowersModerate evidenceFinding

01 · The sentence it was drawn from

“The effect of the trial medications on biomarkers is shown in Table 3, indicating that P. emblica 250 mg, P. emblica 500 mg, and atorvastatin significantly decreased high sensitivity C-reactive protein levels compared with baseline and placebo.”
Quoted verbatim from Effects of Phyllanthus emblica extract on endothelial dysfunction and biomarkers of oxidative stress in patients with type 2 diabetes mellitus: a randomized, double-blind, controlled study.
This finding among the 114 findings on its endpoint

Emblica officinalis

C-reactive protein concentration

lowers

Who
Adults aged 30 to 68 with type 2 diabetes (fasting glucose 110-126 mg/dL, HbA1c 7-9%) and endothelial dysfunction, all on stable metformin 1,500-3,000 mg in every arm; 20 per arm; both amla dose arms reported together; an atorvastatin arm also ran against the same placebo
Dose studied
250 mg or 500 mg twice daily for 12 weeks (two dose arms)

Moderate evidencePMID 23935377 · 2013

02 · The study

Study
RCT
Duration
3 months

Evidence, by strength

  • strong
  • moderatethis finding
  • limited
  • very limited
  • insufficient

03 · The paper

Diabetes, metabolic syndrome and obesity
What else it reported5 findings · 0 compounds · 5 endpoints

04 · To cite this finding

This address does not change

https://catalystproject.ai/e/01M7060VQ4V0RHGHFPD5A9YCMH